Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand.
Philogen Spa and Sun Pharmaceutical Industries Limited announced that they have entered into an exclusive licensing agreement to commercialize Philogen s innovative product, Nidlegy , in Europe,. | May 30, 2023
30.05.2023 - Mumbai, India and Siena, Italy, 30th May 2023 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, “Sun Pharma”)) and Philogen S.p.A . Seite 1
Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich L19TNF is an innovative. | May 25, 2023